智通财经APP获悉，云顶新耀(01952)早盘涨超5%，截至发稿，涨3.49%，报27.24港元，成交额2702万港元。
消息面上，9月17日，据云顶新耀官微消息，公司宣布中国国家药品监督管理局(NMPA)药品审评中心(CDE)已受理维适平®(精氨酸艾曲莫德片，VELSIPITY®)由境外转移至境内生产的药品上市注册申请，并纳入优先审评审批程序。维适平®本地化生产有望于2027年正式投产，将进一步提升其在中国及亚太市场的供应能力，增强供应保障。此次获受理是维适平®商业化战略按计划推进的重要进展。
据介绍，2026年3月维适平®开出首张处方，正式进入中国临床应用阶段。在快速实现商业化落地的同时，维适平®积极参与国家医保目录谈判。在云顶新耀授权区域内，维适平®已在中国大陆、中国香港、中国澳门、新加坡及韩国获得新药上市批准，并有望于2026年下半年在中国台湾获批上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.